An Open-label, Single-dose Phase 1 Clinical Trial to Evaluate the Safety and Effects of Ethnicity and Food on Pharmacokinetics of YH25448 in Healthy Korean and Caucasian Volunteers
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2019
Price : $35 *
At a glance
- Drugs Lazertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Yuhan
- 14 Jan 2019 Status changed from recruiting to completed.
- 06 Sep 2018 Planned End Date changed from 1 Aug 2018 to 1 Aug 2019.
- 06 Sep 2018 Planned primary completion date changed from 1 Aug 2018 to 1 Aug 2019.